Early Responders Lost 21.6% Body Weight in 64-Week Study-Why Timing Matters
Novo Nordisk’s latest clinical data reveal that early responders in a 64-week trial achieved an average 21.6% total body weight loss—a milestone that underscores the potential of GLP-1 receptor agonists ... Read More